Special Issues

December 2019 Highlights from the First Annual Cholangiocarcinoma Summit

Download Issue PDF

Updates on the Understanding of Cholangiocarcinoma


On October 17 and 18, 2019, a group of international experts convened in Phoenix, AZ, for the First Annual Cholangiocarcinoma Summit. The goal of the meeting was to discuss the latest clinical data on the disease, as well as the implications of these findings for providers and patients. Each topic included in the summit was presented by 2 speakers and then analyzed by a chorus of experts in the field. This format was chosen to provide a consensus, whenever possible, on each topic that was presented. [ Read More ]

Medical Management of Patients with Advanced Cholangiocarcinoma


According to several presenters at the First Annual Cholangio­carcinoma Summit, advances in systemic treatment for cholangiocarcinoma (CCA) are emerging, including cytotoxic chemotherapy. Earlier this year, the combination of gemcitabine, cisplatin, and nab-paclitaxel was investigated as first-line therapy in 60 patients with advanced CCA and gallbladder cancer with good performance status.1 Among evaluable patients, the median progression-free survival (PFS) was 11.8 months, the median overall survival (OS) was 19.2 months, and the partial response rate was 45%. Overall, 20% of the patients converted from unresectable to resectable disease and underwent curative surgery. [ Read More ]

Surgery for Cholangiocarcinoma: Before and After


At the First Annual Cholangiocarcinoma Summit, presenters discussed recent advances in the management of patients with cholangiocarcinoma (CCA), including new surgical approaches, the expanding role of liver-directed therapies, radiation, and transplantation, and more effective sequencing of neoadjuvant and adjuvant therapies. [ Read More ]